Cowen and Company reiterated their outperform rating on shares of Thermo Fisher Scientific Inc (NYSE:TMO) in a research report report published on Sunday morning. They currently have a $220.00 target price on the medical research company’s stock, up from their prior target price of $200.00.
Other equities research analysts have also issued reports about the company. Citigroup Inc. reissued a buy rating and set a $201.00 price target (up from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. BidaskClub lowered Thermo Fisher Scientific from a strong-buy rating to a buy rating in a research note on Tuesday, June 27th. Deutsche Bank AG set a $200.00 price target on Thermo Fisher Scientific and gave the stock a buy rating in a research note on Saturday, June 10th. Zacks Investment Research raised Thermo Fisher Scientific from a hold rating to a buy rating and set a $199.00 price target for the company in a research note on Tuesday, July 11th. Finally, Bank of America Corporation reissued a buy rating and set a $210.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Two investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $193.19.
Thermo Fisher Scientific (NYSE TMO) opened at 194.04 on Friday. The stock’s 50 day moving average price is $178.63 and its 200 day moving average price is $169.74. The stock has a market capitalization of $75.70 billion, a PE ratio of 33.80 and a beta of 1.05. Thermo Fisher Scientific has a 1-year low of $139.07 and a 1-year high of $194.30.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The business had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. During the same period last year, the company earned $2.03 EPS. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, equities research analysts predict that Thermo Fisher Scientific will post $9.35 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/09/13/thermo-fisher-scientifics-tmo-outperform-rating-reiterated-at-cowen-and-company.html.
The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.45%.
In other news, VP Seth H. Hoogasian sold 4,140 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 28th. The stock was sold at an average price of $177.80, for a total value of $736,092.00. Following the transaction, the vice president now directly owns 25,518 shares in the company, valued at approximately $4,537,100.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jim P. Manzi sold 11,318 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the completion of the transaction, the director now owns 38,757 shares in the company, valued at $6,702,635.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,738 shares of company stock valued at $4,021,512. 0.49% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in TMO. Proficio Capital Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 71.5% in the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after acquiring an additional 253 shares during the period. Chicago Partners Investment Group LLC purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $108,000. Cribstone Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 8.7% in the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after acquiring an additional 50 shares during the period. Sharkey Howes & Javer increased its holdings in shares of Thermo Fisher Scientific by 1.0% in the 1st quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 7 shares during the period. Finally, Shine Investment Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $113,000. Institutional investors and hedge funds own 83.52% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.